PGD Procedure |
|||||
|
PGD can only be performed on embryos in vitro (in a laboratory). That means this test is always performed in conjunction with an in vitro fertilization cycle.
Embryo Biopsy
The biopsy method is relatively straightforward, but this does not mean that it is an easy procedure to undertake. The embryos are typically biopsied at the pre-implantation stage on day three of development. At this point, the embryo will be composed of between five and twelve cells that are still distinct from each other. By the third day of development, or at the latest on day four, the embryo begins to compact, a process whereby the individual cells lose their clear outline and they seem to fuse together with the other cells to form the morula stage embryo. On the third day, however, single cells can be individually removed without disrupting the adjacent cells in the embryo. Figure: Embryo Biopsy
The embryo during manipulation on the inverted microscope is held in a warm culture medium that helps to allow the cells to be removed with a minimum of trauma to the overall embryo. The removal of up to a quarter of an embryo is not known to be deleterious to the further development of that embryo, as the embryo at this early stage of development can compensate for this loss of material. All cells at this stage are still totipotent, meaning, all are fully capable of directing further embryonic development.
Misdiagnosis Misdiagnosis can occur due to mosaicism within the embryo. Some embryos may contain blastomeres (cells produced by the cleavage [division] of a fertilized egg) which are genetically normal and, within the same embryo, other blastomeres which are abnormal. This is called mosaicism. For this reason, a diagnosis may be incorrect. This may result in the transfer of an embryo carrying a chromosome abnormality or the failure to transfer a normal embryo. Experimental error can also account for a misdiagnosis. Improper cell fixation techniques, DNA denaturation errors, allelic drop-out or amplification of contaminated DNA can lead to a wrong diagnosis. A recent report of the European Society of Human Reproduction and Embryology (ESHRE) documented the PGD results from 25 consortium members from 1999 to 2001. There were 8 confirmed misdiagnoses from 451 PGD tested embryos; 1% (3/305) for chromosome analyses and 3.4% (5/146) for single gene disorders. Are there risks associated with PGD? The micromanipulation techniques used for blastomere biopsy are safe with little risk to the embryo. The risk of accidental damage to the embryo during biopsy is less than 1%. There is no risk to the embryo following chromosomal or single gene defect analysis because the analyzed cells are not put back into the embryo. There may be a slightly lower likelihood of implantation after embryo biopsy compared to an embryo not having been biopsied. Other risks may become apparent over time, but to date appear quite limited and need to be weighed against the potential benefits for each couple.
|
|||||
